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Abstract: Importance: Squamous cell carcinoma (SCC) is the most frequent malignant neoplasm found in
solid organ transplant recipients and is associated with a more aggressive disease course and higher risk of
metastasis and death than in the general population. Objectives: To report the clinicopathologic features
of and identify factors associated with aggressive SCC in solid organ transplant recipients. Methods: This
retrospective multicentric case series included 51 patients who underwent solid organ transplantation and
were found to have aggressive SCC, defined by nodal or distant metastasis or death by local progression
of primary SCC. Standard questionnaires were completed by the researchers between July 18, 2005, and
January 1, 2015. Data were analyzed between February 22, 2016, and July 12, 2016. Results: Of the
51 participants, 43 were men and 8 were women, with a median age of 51 years (range, 19-71 years) at
time of transplantation and 62 years (range, 36-77 years) at time of diagnosis of aggressive SCC. The
distribution of aggressive SCC was preferentially on the face (34 [67%]) and scalp (6 [12%]), followed
by the upper extremities (6 [12%]). A total of 21 tumors (41%) were poorly differentiated, with a
median tumor diameter of 18.0 mm (range, 4.0-64.0 mm) and median tumor depth of 6.2 mm (range,
1.0-20.0 mm). Perineural invasion was present in 20 patients (39%), while 23 (45%) showed a local
recurrence. The 5-year overall survival rate was 23%, while 5-year disease-specific survival was 30.5%.
Conclusions and Relevance: Results of this case series suggest that anatomical site, differentiation, tumor
diameter, tumor depth, and perineural invasion are important risk factors in aggressive SCC in solid organ
transplant recipients.
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C
utaneous squamous cell carcinoma (SCC) is a malig-
nant neoplasm deriving from epidermal keratino-
cytes. In thegeneralpopulation, SCC is the secondmost
common formof keratinocyte carcinomaafter basal cell basal
cell carcinoma,1,2 and inorgan transplant recipients SCC is the
most commonskincancer.1-11Previous studies12-15 report a risk
for nodal metastasis of 1.9% to 4.0% and a risk for disease-
specific death of 1.5% to 2.1% in the general population.
Thenumber of solid organ transplants and long-termsur-
vival in organ transplant recipients have increased over the 5
decades as a result of progress in both surgical techniques and
drug-induced immunosuppression.16 Notwithstanding the
clear benefits of successful allograft transplantation, organ
transplant recipientsexperience importantadverseeffects from
long-term immunosuppressive medication, including a 10-
fold increased risk for malignant neoplasms overall.17,18 In
particular, solid organ transplant recipients have a 65-fold to
250-fold higher incidence of SCC compared with those who
have not received transplants. After transplantation, 20% to
75%of solidorgan transplant recipients are affectedbyat least
1 SCC within 20 years.8,19 After a first invasive SCC, multiple
subsequent SCCs will develop in 60% to 80% of these pa-
tientswithin 3 years. The risk of SCC increases over time,with
the incidence increasing to 40% to 60% at 20 years after
transplantation.20,21
Cutaneous SCC is also associated with a more aggressive
behavior and a higher risk ofmetastasis and death in solid or-
gan transplant recipients than in the general population.6,7,22
The rate of metastasis in solid organ transplant recipients is
reported to be 5% to 8%.23
IMPORTANCE Squamous cell carcinoma (SCC) is the most frequent malignant neoplasm found
in solid organ transplant recipients and is associated with a more aggressive disease course
and higher risk of metastasis and death than in the general population.
OBJECTIVES To report the clinicopathologic features of and identify factors associated with
aggressive SCC in solid organ transplant recipients.
METHODS This retrospective multicentric case series included 51 patients who underwent
solid organ transplantation and were found to have aggressive SCC, defined by nodal or
distant metastasis or death by local progression of primary SCC. Standard questionnaires
were completed by the researchers between July 18, 2005, and January 1, 2015. Data were
analyzed between February 22, 2016, and July 12, 2016.
RESULTS Of the 51 participants, 43 were men and 8were women, with a median age of 51
years (range, 19-71 years) at time of transplantation and 62 years (range, 36-77 years) at time
of diagnosis of aggressive SCC. The distribution of aggressive SCC was preferentially on the
face (34 [67%]) and scalp (6 [12%]), followed by the upper extremities (6 [12%]). A total of 21
tumors (41%) were poorly differentiated, with a median tumor diameter of 18.0mm (range,
4.0-64.0mm) andmedian tumor depth of 6.2 mm (range, 1.0-20.0mm). Perineural invasion
was present in 20 patients (39%), while 23 (45%) showed a local recurrence. The 5-year
overall survival rate was 23%, while 5-year disease-specific survival was 30.5%.
CONCLUSIONS AND RELEVANCE Results of this case series suggest that anatomical site,
differentiation, tumor diameter, tumor depth, and perineural invasion are important risk
factors in aggressive SCC in solid organ transplant recipients.
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In addition to immunosuppression and time from trans-
plantation, the factors for the development of SCC in solid
organ transplant recipients are similar to those found in the
general population, namely, male sex, older age, cumulative
UV radiation exposure, and fair skin.1,7,8,24-28
Although most SCCs will be successfully treated, some
show a very aggressive clinical course. Currently, the distinc-
tion between themany SCCs curedwithout sequelae and the
few SCCswith an aggressive course can be hard tomake at di-
agnosis. Theobjective of this study, basedon aEuropean case
series of solid organ transplant recipients, is to describe clini-
copathologic features of aggressive SCC and to identify fac-
tors that are associated with aggressive development of SCC




erlands; London, United Kingdom; and Zurich, Switzerland,
within the Skin Care in Organ Transplant Patients, Europe
Network.The studyprotocolwasapprovedby theEthicsCom-
mittee of Zurich, Switzerland (NCT02095912), who waived
patient consent for deidentified data.
Inclusion criteria were patients who underwent solid or-
gan transplantation and developed an aggressive SCC includ-
ing nodal or distant metastasis or death by local progression
of primary SCC. All patient identifiers were coded to ensure
patient anonymity. Exclusion criteria were the absence of an
aggressive SCC,mucosal head and neck SCC, ormissing data.
All participating centers were able to identify and retrieve in-
formation on organ transplant recipientswith aggressive SCC
from their archives. Standard questionnaires were com-
pleted by us between July 18, 2005, and January 1, 2015, and
dates of analysis were February 22, 2016, to July 12, 2018. Pa-
tients were followed up from the date of first transplantation
to date of death or the last dermatologist visit. Skin photo-
typeclassificationwasnot recordedbecauseof incompletedata
at the time of inclusion. Datawere obtained from thehospital
database including patient medical records and pathology
reports.
Disease-specific deathwas considered tohaveoccurred if
the treatment team documented that the patient died of a
specific SCC or of complications that arose directly from SCC.
Non–disease-specific death was considered to have occurred
in patients who developed nodal or distant metastasis or a
local, treatment-refractory tumor but died of other causes
(eg, cardiac arrest).
Statistical Analysis
Clinical characteristics were summarized with the use of de-
scriptive statistics and frequency tabulation. Overall sur-
vival, disease-specific survival, progression-free survival, and
time from metastasis to death were analyzed by the Kaplan-
Meier method. Statistical analysis was performed with IBM
SPSS statistical software, version 23.0. (SPSS Inc). No signifi-
cance testing was performed.
Results
Most of the 51 solid organ transplant recipients who devel-
oped an aggressive SCC were men (43 [84%]) and had re-
ceived a kidney transplant (40 [78%]). Median age at diagno-
sis of aggressive SCCwas 62 years (range, 36-77 years). Three
patients (6%)underwentcombinedkidneyandpancreas trans-
plantation and 1 patient had a liver and lung transplant. Ten
patients (20%) underwent 2 transplantations because of or-
gan failure. Full characteristics of the study population are
summarized in Table 1.
The most common primary site for SCC was the face (34
[67%]) (Table 2). The median diameter of aggressive SCC
was 18.0 mm (range, 4.0-64.0 mm), with a median depth
of invasion of 6.2 mm (range, 1.0-20.0 mm). A total of 21
tumors (41%) were histologically classified as poorly differ-
entiated and perineural invasion was identified in 20 of the
SCCs (39%). The local recurrence rate was 45% (n=23).
Tumor characteristics are listed in detail in Table 2. The
Figure shows overall survival, disease-specific survival,
progression-free survival, and time from metastasis to
death overall by Kaplan-Meier analysis. Figure, A shows
that 50% overall survival was reached at 28.0 months (95%
CI, 21.3-34.7 months) and mean (SD) 5-year overall survival
was 23.0% (6.4%), while mean (SD) 10-year survival was
11.3% (5.5%). Figure, B shows that 50% disease-specific sur-
vival was reached at 33.0 months (95% CI, 0.9-45.1 months)
and mean (SD) 5-year disease-specific survival was 30.5%
(7.6%), while mean (SD) 10-year survival was 25.9% (7.1%).
Figure, C shows that mean (SD) 5-year and 10-year
progression-free survival were 5.0% (1.3%) (95% CI, 2.5-7.3
years). Median time from metastasis to death was 12.0
months (95% CI, 3.8-20.2 months) (Figure, D). Almost all
SCCs showed progression within 2 years from diagnosis.
Discussion
Patient Characteristics
Most of our solid organ transplant recipients weremale, with
amedianageof 51 years at the timeof transplantationandme-
dian age of 62 years at diagnosis of aggressive SCC. This find-
Key Points
Question What factors are associated with aggressive squamous
cell carcinoma in solid organ transplant recipients?
Findings In this case series study of 51 patients, aggressive
squamous cell carcinomas were preferentially localized on the face
in 34 patients (67%). A total of 21 tumors (41%) were poorly
differentiated, with a median tumor diameter of 18mm and
median tumor depth of 6.2 mm.
Meaning As suggested by results of this case series, anatomical
site, differentiation, tumor diameter, tumor depth, and perineural
invasion are important risk factors in aggressive squamous cell
carcinoma in solid organ transplant recipients.
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ing is in agreement with those of Pinho et al,29 who reported
on keratinocyte carcinoma,with amedian patient age of 54.5
years at transplantation and 61.9 years at diagnosis of aggres-
sive SCC. In contrast to our data, there was no difference in
terms of sex in their study. In a study by Lott et al,22 SCC in
solid organ transplant recipients occurred earlier, at a me-
dian age of 57 years, compared with immunocompetent pa-
tients, who developed SCC at a median age of 67 years.22 Al-
though our case series was not selected in a randomized
fashion, our patient characteristics suggest that our series is
typical for solid organ transplant recipients.
Tumor Characteristics
The body site for aggressive SCC in our study was preferen-
tially on the face and scalp, followed by the upper extremi-
ties. Rabinovics et al30 similarly report a high number of SCC
in the head and neck region, with a 24% incidence of aggres-
sive (local recurrence, nodal, or distant metastasis) head and
neck SCC in solid organ transplant recipients, comparedwith
other aggressivemalignant neoplasms occurring on the head
and neck. Pinho et al29 found keratinocyte cancer on UV-
exposed sites for 83% of SCCs and 87% of basal cell carcino-
mas.
Most tumors in our series were poorly or moderately dif-
ferentiated. The presence of poor differentiation indicates a
poorer prognosis. Brantsch et al13demonstrate a 3-foldhigher
risk for local recurrence and a 2-fold higher risk for metasta-
sis comparedwithwell-differentiatedSCCs.Mullenetal31dem-
onstrate a 2.9-fold higher risk ofmetastasis or death in poorly
differentiated tumors compared with well-differentiated or
moderately differentiated tumors.
The median tumor diameter in our study was 18 mm
(range,4-64mm).Thisdiameter is slightlysmaller thanaSwed-
ish cohort in which aggressive SCCs were 20mm in diameter
or larger.32 Based on a meta-analysis by Thompson et al,33
Table 1. Patient Characteristics




Age, median (range), y
At time of transplantation 51 (19-71)






Kidney and pancreas 3 (6)
Liver and lung 1 (2)
Survival status at last follow-up
Alive 7 (14)
Death due to SCC 32 (63)
Death due to other causes 12 (24)
Abbreviation: SCC, squamous cell carcinoma.
Table 2. Tumor Characteristics
Characteristic No. (%) (N = 51)





Arm or hand 6 (12)
Genitalia 2 (4)
Histologic classification of SCC
Well differentiated 10 (20)
Moderately differentiated 15 (29)
Poorly differentiated 21 (41)
Spindle cell morphologic characteristics 2 (4)
Desmoplastic 3 (6)
Primary tumor, median (range), mm
Diameter of SCC 18.0 (4-64)
Total No. (No. missing) 50 (1)
Depth of invasion 6.2 (1-20)
Total No. (missing) 48 (3)
Tumor-free margins on histologic examination 2.0 (0-15)
Total No. (No. missing) 38 (13)
Clark level of invasionb
Level I 1 (2)
Level II 1 (2)
Level III 0
Level IV 14 (28)
Level V 33 (65)








Missing data 7 (14)
Metastasis sitec
No metastasis 6 (12)
Lymph nodes 30 (59)








Abbreviation: SCC, squamous cell carcinoma.
a An aggressive SCC was defined by regional metastasis (lymph nodes or parotid
gland); distant metastasis including liver, lung, brain, or bone; or a local,
therapy-resistant progression of primary SCC.
bClark level I is confined to the epidermis, level II penetrates the papillary
dermis, level III fills the papillary dermis, level IV extends into reticular dermis,
and level V invades subcutis.
c Metastasis location was counted for every patient; some hadmultiple organ
metastasis.
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tumor diameter larger than 2 cm is the risk factormost highly
associatedwithdisease-specificdeathanda 19-foldhigher risk
of death fromSCCcomparedwith tumorswith adiameter less
than 2 cm.
Themedian tumor thickness in our studypopulationwas
6.2 mm. This risk factor is highly associated with recurrence
andmetastasis, with tumor thickness greater than 2mmhav-
ing a 10-fold higher risk of local recurrence and 11-fold higher
riskofmetastasis.33 InaprospectivestudybyBreuningeretal,34
tumordepthgreater than4mmwas linked to ametastasis rate
of 9%, increasing to ametastasis rate of 16% for a tumor thick-
ness of 6 mm or more.
Perineural invasion (39%)and local recurrence (45%)were
frequent in our study, but will have been selected for in a co-
hort of patients with aggressive SCC. In the general popula-
tion, perineural invasion is rare, with an incidence of 2.5% to
5.0%forprimarySCCs, and is associatedwitha4-fold to5-fold
increased risk of nodalmetastasis anddeathdue to SCC.35Lo-
cal recurrence is reported to occur in 7% to 16%of all patients
with SCC and is more frequent when there is perineural
invasion.30,36
The most common location of metastasis in the solid or-
gan transplant recipients in our study was the lymph nodes,
including the parotid gland and skin. Lindelöf et al32 demon-
strated that all lethal SCCs (7 of 544 SCCs in a cohort of 5931
solidorgantransplant recipients)were locatedonthehead,and
that the parotid gland was the principal site for metastasis. A
retrospective study by Lott et al22 found a 3.5 higher risk for
solid organ transplant recipients to develop lymph nodeme-
tastasis comparedwith the tumors in the immunocompetent
control group.
Survival
Our study demonstrated a poor prognosis of aggressive SCC,
with a 5-year overall survival rate of 23% and a 5-year
disease-specific survival rate of 30.5%. Rabinovics et al30
showed a 5-year survival rate of 67.7% and 10-year survival
rate of 40.0% in patients with SCC; however, that study
included nonaggressive SCC. Lott et al22 reported a 3-year
disease-specific survival rate of 56% for metastatic SCC in
solid organ transplant recipients. A study by Mullen et al31
showed a 5-year overall survival rate of 35% and a 5-year
disease-specific survival rate of 50% in patients with
aggressive SCC of the trunk or extremities. In summary, our
case series in solid organ transplant recipients shows an
unfavorable survival for those with primary SCC with
aggressive features, comparable with that seen in other
reports.
Limitations
This study is limited by its retrospective design, the limited
number of patients, and number of contributing centers.
Figure. Squamous Cell Carcinoma (SCC) Overall Survival, Disease-Specific Survival, Progression-Free Survival,
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A, An overall survival of 50%was
reached at 28.0months (95% CI,
21.3-34.7 months). Mean (SD) 5-year
overall survival was 23.0% (6.4%),
while mean (SD) 10-year overall
survival was 11.3% (5.5%).
B, A disease-specific survival of 50%
disease-specific survival was reached
at 33.0months (95% CI, 0.9-45.1
months). Mean (SD) 5-year
disease-specific survival was 30.5%
(7.6%) andmean (SD) 10-year
disease-specific survival was 25.9%
(7.1%). C, Mean (SD) 5- and 10-year
progression-free survival were 5%
(1.3%) (95% CI, 2.5-7.3 years).
D, Median time frommetastasis to
death was 12 months (95% CI,
3.8-20.2 months). Tick marks indicate
censoring.
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There is an implict bias in selecting tumors with a poor out-
come (ie, recurrence, metastasis, and death) toward clinical
and pathologic factors known to be associated with
poor outcomes, such as perineural invasion. Another
limitation is the lack of a control group (solid organ trans-
plant recipients without development of aggressive SCC).
Data on ethnicity, skin type, and sun exposure were not
available.
Conclusions
Taken together, our case series confirms that anatomical
site, differentiation, tumor diameter, tumor depth, and peri-
neural invasion are important risk factors in aggressive SCC
in solid organ transplant recipients. We also demonstrated a
poor prognosis of aggressive SCC.
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